Accueil・Liste d'Actions・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Fermé

3.53 -14.53

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.5

Max

3.61

Chiffres clés
By Trading Economics
Revenu	-42M -78M
BPA	-0.59
Employés	106
EBITDA	-42M -77M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+148.03% upside

Dividendes
By Acuity
Prochains Résultats	6 nov. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-34M 297M
Ouverture précédente	18.06
Clôture précédente	3.53

Zentalis Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

15 août 2026, 23:51 UTC

U.S. Industrial Production MoM data set for August 18, 2026, amid mixed economic signals and a forecasted increase of only 0.3%.

15 août 2026, 23:51 UTC

Bitcoin is trading roughly flat during Saturday's session, remaining near the lower end of its one-month trading range and below its 20-day moving average.

15 août 2026, 23:41 UTC

U.S. equities pull back amid disappointing retail sales and consumer sentiment, while geopolitical tensions and upcoming FOMC Minutes raise concerns for market stability.

15 août 2026, 23:41 UTC

European equity and bond markets closed for holiday as U.S. consumer sentiment drops, raising concerns over economic stability ahead of key data releases.

15 août 2026, 23:41 UTC

French, Italian, and Spanish markets closed for holiday as U.S. consumer sentiment drops sharply, raising concerns over inflation and potential Federal Reserve rate hikes.

15 août 2026, 23:41 UTC

Market Complacency Amidst Bond Volatility: U.S. Stocks Slip as Consumer Sentiment Falls and Retail Sales Decline, While Crypto Shows Resilience.

15 août 2026, 23:41 UTC

Cautious Optimism for Stabilization in Canadian Housing Prices Ahead of August 20 Index Release Amid Mixed Economic Signals.

15 août 2026, 23:41 UTC

Market Analysts Brace for Philadelphia Fed Manufacturing Index Release Amid Disappointing Retail Sales and Economic Uncertainty.

15 août 2026, 23:31 UTC

China's House Price Index YoY release on August 17, 2026, shows cautious optimism as home price declines ease amid mixed economic sentiment and global investor confidence.

15 août 2026, 23:11 UTC

Cautious Market Sentiment Ahead of July 2026 Building Permits Data Release, Forecasting 1.37 Million Issued Amid Recent Volatility

15 août 2026, 23:11 UTC

Australia's Westpac Consumer Confidence Index set for release amid cautious market sentiment and global economic uncertainties.

15 août 2026, 23:01 UTC

Upcoming Housing Starts Data Release on August 18, 2026, Amid Concerns Over Consumer Spending and Inflation Impacting Real Estate Markets.

15 août 2026, 23:01 UTC

U.S. Import Prices Expected to Rise 0.1% Amid Positive Inflation Sentiment and Reduced Fed Rate Hike Expectations

15 août 2026, 23:01 UTC

U.S. Export Prices Expected to Drop 0.2% Amid Slowing Inflation and Weak Retail Sales, Influencing Fed's Interest Rate Decisions

15 août 2026, 23:01 UTC

Market Awaits U.S. Building Permits Data Amid Optimism for Construction Growth and Infrastructure Investments.

15 août 2026, 23:01 UTC

U.S. Housing Starts Data for July 2026 Set to Release on August 18, Amid Mixed Market Sentiment and Forecast of 1.35 Million Units

15 août 2026, 23:01 UTC

EUR/CAD is trading roughly flat during after-market hours, showing little change since Friday's close and remaining near the lower end of its one-month range.

15 août 2026, 22:51 UTC

Australia's Westpac Consumer Confidence Index set for August 18, 2026 release amid global economic uncertainties and mixed market performance.

15 août 2026, 22:51 UTC

Canada's July 2026 Housing Starts Data Release Expected at 248K Amid Cautious Market Sentiment and Volatile Trends.

15 août 2026, 22:51 UTC

Japan's Core Inflation Rate Expected to Rise to 1.8% YoY Amid Global Economic Pressures and Potential BoJ Interest Rate Hike

15 août 2026, 22:51 UTC

Japan's July Exports YoY Data Set for Release Amid Optimistic Market Sentiment and Strong Nikkei Performance.

15 août 2026, 22:51 UTC

Japan's July trade balance expected to show a -680 billion yen deficit amid rising import costs and weak yen, while equities gain on Wall Street optimism.

15 août 2026, 22:51 UTC

Japan's Inflation Rate Release on August 20 Expected to Impact Monetary Policy and Market Sentiment Amid Anticipated Interest Rate Hikes.

15 août 2026, 22:41 UTC

NY Empire State Manufacturing Index Set for Release Amid Caution Over Disappointing Retail Sales and Economic Sentiment.

15 août 2026, 22:41 UTC

Canada's Inflation Rate Expected to Rise 0.5% in July Amid Mixed Market Sentiments and External Economic Pressures

15 août 2026, 22:41 UTC

MBA 30-Year Mortgage Rate Release on August 19 Expected to Impact Housing Market Amid Cooling Inflation and Interest Rates

15 août 2026, 22:41 UTC

Canada's July Inflation Rate Expected to Rise from 2.8% to 3%, Amid Geopolitical Tensions and Supply Chain Disruptions

15 août 2026, 22:41 UTC

Canada's Core Inflation Rate Release on August 17, 2026, Sparks Caution Among Investors Amid Geopolitical Tensions and Trade Uncertainty.

15 août 2026, 22:41 UTC

Avalanche is trading lower today, with no specific news identified. The asset remains within its one-month range amid shifting investment patterns among younger investors.

15 août 2026, 22:32 UTC

Japan's Machinery Orders MoM data set for August 18, 2026, with a forecasted increase of 0.079%, amid positive stock market sentiment and investor confidence in capital spending.

Comparaison

Variation de prix

Zentalis Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

148.03% hausse

Prévisions sur 12 Mois

Moyen 8.83 USD 148.03%

Haut 11 USD

Bas 5 USD

Basé sur 6 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

6 ratings

Achat

Maintien

Vente

Basé sur 6 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.